UnitedHealthcare Rhinoplasty Coverage Update | OpenPayer

Loading...

UnitedHealthcare Rhinoplasty Coverage Update | OpenPayer

Coverage and Medical Necessity Criteria

Nasal valve/vestibular stenosis/alar collapse — Medical necessity

Covered when ALL of the following are met

nasal_valve_coverage: Prolonged, Persistent, Obstructed nasal breathing due to internal and/or External Nasal Valve compromise; and Other causes of nasal obstruction have been adequately treated with maximal therapy and nasal obstruction persists; and Nasal septal deviation and turbinate hypertrophy either are not present, have been previously surgically treated, or are scheduled to be surgically treated at the same time as the nasal valve procedure; and Documented evidence of visible collapse of the alar (lower lateral) cartilage and/or lateral nasal wall with deep inspiration; and Documented evidence of subjective and audible improvement in nasal airflow during modified Cottle maneuver; and Photos clearly document dynamic collapse or anatomical deformities narrowing the internal and/or External Nasal Valve consistent with the clinical examination; and The surgeon has clearly described whether the nasal valve compromise is static or dynamic, which valve(s) are involved, and provided a plainly stated surgical plan including the need for a cartilage graft.

From policy coverage rationale

Rhinophyma excision — Medical necessity

Covered when ALL of the following are met

rhinophyma_coverage: Either prolonged, Persistent, Obstructed nasal breathing due to rhinophyma OR chronic infection or bleeding unresponsive to medical management due to rhinophyma; and Photos clearly document rhinophyma as the primary cause of an anatomical Mechanical Nasal Airway Obstruction or chronic infection consistent with the clinical examination; and The proposed procedure is designed to correct the anatomical Mechanical Nasal Airway Obstruction and relieve the Nasal Airway Obstruction by correcting the deformity, or the proposed procedure is designed to address the chronic infection.

From policy coverage rationale

Rhinoplasty for congenital anomalies — Medical necessity

Covered when the following are present

rhinoplasty_congenital: Rhinoplasty performed for a nasal deformity associated with congenital craniofacial anomalies (including but not limited to Pierre Robin, Apert, Fraser, Binder, Goldenhar syndromes, nasal dermoids, Tessier nasal clefts) or associated with a cleft lip or cleft palate.

From policy coverage rationale

Rhinoplasty - primary — Medical necessity

Covered when ALL of the following are met

rhinoplasty_primary: Indication is prolonged, Persistent, Obstructed nasal breathing due to nasal bone and septal deviation as the primary cause, or nasal fracture with displacement causing obstruction, or residual large cutaneous defect after malignancy/trauma; and The Nasal Airway Obstruction cannot be corrected by septoplasty alone, as documented in the medical record; and Photos clearly document the nasal bone/septal deviation as the primary cause consistent with the clinical examination; and The proposed procedure is designed to correct the anatomical Mechanical Nasal Airway Obstruction by centralizing the nasal bony pyramid and straightening the septum; and Nasal Airway Obstruction is causing significant symptoms; and Obstructive symptoms persist despite conservative management for 4 weeks or greater (including nasal steroids or immunotherapy where appropriate).

From policy coverage rationale

Rhinoplasty - revision and tip — Medical necessity

Covered when ALL of the following are met

rhinoplasty_revision_tip: Revision: required as treatment of complication or residual deformity from primary surgery performed to address a Functional Impairment when a documented Functional Impairment persists due to the complication; and Photos clearly document the secondary deformity/complication as the primary cause of an anatomical Mechanical Nasal Airway Obstruction consistent with exam; and The proposed procedure is designed to correct the anatomical Mechanical Nasal Airway Obstruction or treat the complication; and Nasal Airway Obstruction is causing significant symptoms; and Obstructive symptoms persist despite conservative management for 4 weeks or greater. Tip: prolonged, Persistent, Obstructed nasal breathing due to tip drop as the primary cause; and Photos clearly document tip drop as the primary cause consistent with exam; and The proposed procedure is designed to lift the nasal tip to relieve obstruction; and Nasal Airway Obstruction is causing significant symptoms; and Obstructive symptoms persist despite conservative management for 4 weeks or greater.

From policy coverage rationale

Nasal polypectomy — Medical necessity per InterQual

Covered when InterQual criteria met

nasal_polypectomy: Nasal polypectomy is considered reconstructive and medically necessary in certain circumstances per InterQual CP: Procedures, Polypectomy, Nasal; refer to InterQual criteria for specific clinical indications and requirements.

Policy directs to InterQual criteria

Evidence and society guidance supporting coverage with objective documentation

Coverage context and supporting statements from literature and specialty societies

Society support for functional/reconstructive nasal surgery: AAO-HNS and ASPS recognize surgical repair and nasal surgery as appropriate to improve nasal airway function and for reconstructive indications.

References: AAO-HNS position (2023); ASPS Nasal Policy Statement (2021)

Evidence quality: Available studies are largely low-level (case series, single-center retrospective) with few RCTs; conclusions recommend more robust RCTs and multicenter trials.

Systematic reviews and meta-analyses note heterogeneity and low evidence levels.

Outcome measurement: Objective measures (rhinomanometry, acoustic rhinometry) and validated patient-reported outcomes (NOSE, SNOT-20) are used in studies and should be part of documentation for assessing benefit.

Multiple studies reported pre- and post-operative NOSE and rhinomanometry results.

Absorbable nasal implant (Latera) — evidence and coverage considerations

Evidence supports symptom improvement with absorbable lateral wall implants in selected patients with dynamic nasal valve collapse, but studies have methodological limitations.

General evidence summary: Randomized and nonrandomized studies report statistically significant improvements in NOSE and VAS scores with Latera in some cohorts up to 24 months, but many studies are single-arm, have short control follow-up, adjunctive procedures, small samples, and subjective endpoints.

See Kim et al., Stolovitzky et al., and ECRI/Hayes reviews.

Implication for coverage decision: Consider coverage when documentation shows dynamic lateral wall collapse is a primary contributor to NAO and baseline and planned outcome measurements (e.g., NOSE) are provided; otherwise evidence quality concerns may justify noncoverage or further review.

AAO-HNS and ARS statements emphasize clinician judgment and need for higher-quality data.

Septal swell body (SSB/NSB) reduction — evidence and coverage considerations

Procedures to reduce septal swell body (TCRF/RFA/coblation/microdebrider) show symptomatic benefit in small studies and meta-analysis up to 12–24 months, but randomized controlled data and long-term outcomes are limited.

General evidence summary: Systematic reviews and prospective single-arm studies report significant reductions in NOSE and related scores after SSB reduction with TCRF or other energy-based methods; adverse events are uncommon but data are limited by small sizes and lack of robust control groups.

See Kim et al. 2025 meta-analysis and Pritikin et al. studies.

Implication for coverage decision: Consider coverage when clear anatomic SSB hypertrophy contributing to NAO is documented with preprocedure symptom scores and failure or inadequacy of conservative measures, recognizing evidence is limited and follow-up requirements may be needed.

Long-term durability beyond 12–24 months is not well-established.

PNN/SPG Ablation — eligibility

Covered when ALL of the following are met (evidence-derived eligibility elements used in trials):

Eligibility for PNN/SPG ablation: 1) Chronic rhinitis symptoms ≥ 6 months; and 2) Inadequate symptom control after a trial of medical therapy (intranasal corticosteroids, antihistamines, and/or anticholinergics); and 3) Baseline validated symptom score meeting study thresholds (examples used in trials: 24-hour rTNSS ≥ 6 with rhinorrhea subscore ≥2 and congestion subscore ≥1); and 4) Candidate for in‑office procedure under local anesthesia.see text

Derived from eligibility criteria reported in multiple RCTs and cohort studies.

Septal body / NSB reduction — eligibility

Consider coverage when ALL of the following are met:

Septal body (NSB/NST) reduction candidacy: 1) Symptomatic nasal obstruction attributable to septal body (NSB/NST) hypertrophy demonstrated on exam or imaging; and 2) Refractory to appropriate medical therapy; and 3) Documentation of objective or validated subjective measures (e.g., acoustic rhinometry, VAS, NOSE, SNOT-22) showing significant baseline impairment.study examples: mean NSB width ~16 mm; follow-up 3–12 months

Evidence includes small prospective and retrospective studies and one RCT showing short-term improvements.

Common trial-based coverage criteria

Covered when ALL of the following are documented (as commonly required in clinical trials):

Baseline severity: Validated symptom score at baseline consistent with trial thresholds (examples: rTNSS ≥6 for chronic rhinitis; NOSE ≥60 for nasal valve/NAO).see thresholds

Supported by enrollment criteria in randomized and single-arm studies

Medical therapy failure: Inadequate response to appropriate medical therapy documented before procedure (e.g., ≥4 weeks of intranasal steroids where applicable).duration and therapy per study examples

Multiple studies required prior medical management

Objective/subjective assessment: Documentation of pre- and post-procedure patient-reported outcome measures (rTNSS, NOSE, RQLQ) to assess response using validated instruments.

Evidence, regulatory context, and documentation criteria

Evidence and regulatory information relevant to consideration of coverage for nasal valve and related procedures

Key supportive evidence: Randomized controlled trials (e.g., Silvers et al., Stolovitzky et al.) demonstrated higher responder rates for active treatments (TCRF or bioabsorbable implant) versus sham at short-term follow-up with significant NOSE or rTNSS improvements.

Short-term follow-up and investigator unmasking are limitations.

Regulatory context: Several devices (VivAer, ClariFix, RhinAer, Latera) have FDA 510(k) clearance or classification information; FDA clearance is informational only and not by itself a basis for coverage.

Refer to specific 510(k) IDs in coding module.

Documentation requirement for coverage review: Medical records documentation that fully supports medical necessity (history, physical examination, diagnostic tests, and photos) may be required to determine coverage eligibility; documentation must be made available upon request.

Benefit coverage is governed by federal, state, or contractual plan terms.

Procedures performed for nasal conditions not explicitly described as reconstructive in this policy (for example, cosmetic rhinoplasty or other appearance-focused operations) are not considered reconstructive and medically necessary unless the specific reconstructive criteria listed for each procedure are met. The policy defines reconstructive indications (e.g., nasal valve repair, rhinophyma excision, functional rhinoplasty) and limits coverage to those documented anatomic or functional reasons that satisfy the stated medical necessity elements.

Examples of reconstructive indications that must be documented to support coverage include prolonged, persistent obstructed nasal breathing from valve compromise, rhinophyma causing mechanical obstruction or refractory infection/bleeding, congenital craniofacial deformities, and primary nasal bone/septal deformities causing airway obstruction; absent such documentation, the procedure is not considered reconstructive or medically necessary.

The policy lists several specific procedures and device-based interventions that are considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy. These include absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body (NSB/ NST) reduction, posterior nasal nerve or sphenopalatine ganglion ablation by radiofrequency or cryoablation (e.g., RhinAer, ClariFix), and radiofrequency treatment of nasal valves (e.g., VivAer ARC Stylus).

The document describes the Latera device as an absorbable polylactic acid implant that provides lateral wall support and absorbs over approximately 2 years, leaving a collagen track; however, available clinical studies are limited by short follow-up, heterogeneous adjunctive procedures, and low overall quality, which underpins its classification here as unproven for routine coverage.

Many of the newer techniques and devices discussed in the policy have limited long-term evidence. Systematic reviews and evidence summaries note that most studies are single-arm case series, retrospective cohorts, or small randomized trials with short follow-up and methodological limitations, and authors consistently call for larger multicenter RCTs with longer-term outcomes to establish durability and comparative effectiveness.

Because long-term randomized data and robust comparative studies are lacking for several of these approaches, the policy cautions that the absence of demonstrated long-term benefit may limit coverage unless strong, case-specific documentation justifies the intervention.

Comparative evidence directly evaluating newer nasal procedures versus standard reconstructive approaches such as rhinoplasty with autologous cartilage grafting is limited. Systematic reviews found few high-quality comparative trials and concluded that the literature emphasizes technique descriptions over patient‑reported, comparative outcomes.

Consequently, the lack of head-to-head trials comparing devices or minimally invasive valve procedures to rhinoplasty or graft-based repairs constrains conclusions about relative effectiveness and supports careful case-level review when these alternatives are proposed.

Evidence summaries for interventions targeting the nasal septal turbinate/swell body note that isolated cautery or cryosurgery did not demonstrate benefit in at least one prospective study. The policy therefore indicates that isolated cautery or cryosurgery of the NST/NSB without evidence of comparative clinical benefit may be excluded or considered non-preferred.

When considering these energy-based approaches, reviewers should note the specific method studied (e.g., RFA, coblation, microdebrider) and that some modalities (RFA, coblation, submucosal reduction) showed benefit in small studies while cautery/cryosurgery did not.

The policy summarizes Hayes evolving-evidence reviews indicating that evidence for RhinAer and similar posterior nasal nerve ablation techniques is limited and evolving. While some studies report clinically meaningful symptom relief, the reviews found study quality variable and concluded evidence does not yet permit definitive conclusions about comparative effectiveness.

Hayes updates and other summaries note ongoing trials but emphasize that current data are insufficient to determine whether RhinAer provides superior, equivalent, or inferior outcomes compared with alternative treatments.

The policy explicitly states that FDA approval or clearance alone is informational and is not a basis for coverage. FDA device classifications and 510(k) clearance are provided for context, but coverage decisions depend on clinical evidence, medical necessity, and applicable federal, state, or contractual rules.

For example, the VivAer Stylus is noted to have received 510(k) clearance in March 2020 for use in ENT surgery, but the policy reiterates that such regulatory status does not by itself establish that a device or procedure is medically necessary under covered benefits.

Procedures and devices that the policy lists as unproven (for example, Latera implants, NSB reduction, PNN/SPG ablation devices, and some radiofrequency valve treatments) are considered not medically necessary for the indications described because the available evidence is insufficient to establish safety and efficacy.

Requests for these listed interventions should generally be denied as not medically necessary unless compelling, well-documented, patient-specific justification and objective documentation of anatomic cause and expected benefit are provided and accepted upon review.

Where existing evidence is limited to low-quality studies (single-arm cohorts, small nonrandomized comparisons, or short follow-up), the policy indicates such procedures may not be covered. The policy emphasizes that procedures supported only by low-quality evidence or lacking comparative data and objective outcomes are at higher risk of being considered not medically necessary.

Examples include absorbable lateral wall implants and several newer device-based valve or neuroablation therapies, for which systematic reviews and evidence syntheses have highlighted methodological weaknesses and risk of bias.

The policy requires objective documentation that an anatomic lesion is the primary cause of nasal airway obstruction in order to support coverage. Interventions proposed without objective demonstration of the anatomic contributor (for example, no photos, maneuvers, or exam findings showing valve collapse) or without validated symptom severity measures may be considered not medically necessary.

Clinical documentation should include exam findings (e.g., visible alar or lateral wall collapse), modified Cottle maneuver results, and photographs consistent with the clinical assessment to show that the planned intervention addresses a documented anatomic cause.

The policy references Hayes reviews noting that evidence for both ClariFix cryotherapy and RhinAer is limited and evolving. Hayes concluded minimal or unclear support for ClariFix and that RhinAer evidence does not yet permit conclusions regarding comparative effectiveness.

These assessments support the policy's cautious stance and the need for higher-quality trials before routine coverage is endorsed for these technologies.

Devices and procedures without robust comparative effectiveness data, long-term durability outcomes, or consistent objective outcome measures may be restricted or not covered. The policy specifically notes limited comparative data for approaches such as radiofrequency remodeling (VivAer) and some newer implant or neuroablation technologies.

When comparative trials or long-term follow-up are lacking, the policy indicates coverage may be limited pending stronger evidence or clear documentation that an individual patient's anatomy and prior therapy justify the intervention.

Requests lacking sufficient clinical documentation to establish that the policy's medical necessity criteria are met may be rendered unsupported. The policy specifies that medical records must contain a relevant history, physical examination, and results of pertinent tests or procedures and that documentation must fully support the need for the requested service.

Examples of documentation that may be requested include photographs showing valve collapse or rhinophyma, modified Cottle maneuver findings, description of static versus dynamic compromise, and a clear surgical plan describing graft requirements. Absence of these items can lead to a finding of insufficient documentation and noncoverage.

Applicable Codes and Coding Notes

Applicable CPT/HCPCS Codes (listed)mixed

30117	Excision or destruction (e.g., laser), of intranasal lesion; internal approach.
30120	Excision or surgical planing of skin of nose for rhinophyma.
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip.
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip.
30420	Rhinoplasty, primary; including major septal repair.
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work).
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies).
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies).
30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only.
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies.

1–10 of 18

1/2

No explicit codes in this document portionmixed

No codes listed

FDA product code referencedmixed

LRC	FDA product code for instrument; ear, nose, and throat (ENT); manual surgical (broad ENT device category)

FDA 510(k) referencemixed

K200300

VivAer Stylus 510(k) clearance ID

FDA device/product codes and 510(k) IDsmixed

LRC	FDA product code: instrument; ear, nose, and throat; manual surgical (devices used for rhinoplasty and other sinus surgeries)
LYA	FDA product code for intranasal septal splint devices (Class I)
K200300	VivAer Stylus 510(k) ID (March 2020)
K161191	Latera Absorbable Nasal Implant 510(k) ID (June 23, 2016)
K190356	ClariFix Device 510(k) ID (February 14, 2017)
K221907	RhinAer Stylus 510(k) ID (July 29, 2022)

Conservative management duration — policy requirements

Required durationConservative management for obstructive symptoms is required for at least 4 weeks in some rhinoplasty indications; the definitions section also cites 6 weeks for prolonged obstruction

Included therapiesExamples of conservative management include nasal corticosteroids and antihistamines (and immunotherapy where appropriate)

PurposeEstablish failure of maximal medical therapy before considering reconstructive nasal procedures

Documentation expectationMedical records should document duration and type of conservative therapies tried and lack of adequate symptom relief

rTNSS enrollment thresholds reported in trials

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization and coding review

Prior authorization/review may be required for functional or reconstructive nasal surgery. Procedures intended to improve airway function (reconstructive/functional rhinoplasty, nasal valve repair, repair of nasal vestibular stenosis, alar collapse, rhinophyma excision) should be evaluated and documented as functional when airway benefit is intended. Coding review may occur and listed codes do not guarantee coverage.

Prior authorization may be required for reconstructive/functional nasal procedures
All nasal surgical claims may be subject to coding review

Prior Authorization

Prior authorization — functional/reconstructive nasal surgery

Functional or reconstructive nasal surgery (including nasal valve repair, alar/vestibular repair, and rhinoplasty performed to correct anatomic causes of airway obstruction) submitted for prior authorization should be accompanied by documentation that the procedure is intended to provide airway benefit rather than cosmetic benefit.

Clinical Background and Scope

Background: Nasal airway obstruction (NAO) can result from bony or cartilaginous deformities, dynamic or static nasal valve compromise, rhinophyma, or congenital anomalies; these are the principal anatomic causes addressed by the policy.

Procedures described in the policy — including rhinoplasty variants (primary, revision, congenital), nasal valve repair techniques, and rhinophyma excision — aim to correct anatomic Mechanical Nasal Airway Obstruction after failure of appropriate medical therapy, with documentation (exam, maneuvers, and photos) identifying the deformity as the primary cause and guiding the reconstructive plan.

Key Definitions

Mechanical Nasal Airway Obstruction definition

DefinitionMechanical Nasal Airway Obstruction: Trouble breathing through the nose (not snoring) due to a bony or cartilaginous deformity

Clinical relevanceUsed to identify anatomical causes of nasal obstruction that may require reconstructive surgical correction

Exclusion noteDrug-induced rhinitis and non‑anatomic causes should be excluded when diagnosing mechanical obstruction

External Nasal Valve definition

DefinitionExternal Nasal Valve: The entrance to the nose including the caudal edge of the lateral crus of the lower lateral cartilage, soft tissue alae, membranous septum, and sill

Anatomic scopeEncompasses lower lateral cartilage and surrounding soft tissue that contribute to initial airflow resistance

Policy Updates and Changes